Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) price on Friday, June 13, rose 1.09% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $307.99.
A look at the stock’s price movement, the close in the last trading session was $304.67. Turning to its 52-week performance, $310.22 and $152.30 were the 52-week high and 52-week low respectively. Overall, ALNY moved 15.11% over the past month.
Alnylam Pharmaceuticals Inc’s market cap currently stands at around $40.16 billion, with investors looking forward to this quarter’s earnings report slated for in July.
20 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 16 recommend ALNY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ALNY’s current price about 3.44% and 14.35% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 64.12, while 7-day volatility ratio is 1.50% and 1.52% in the 30-day chart. Further, Alnylam Pharmaceuticals Inc (ALNY) has a beta value of 0.21, and an average true range (ATR) of 9.50. Analysts have given the company’s stock an average 52-week price target of $324, forecast between a low of $310 and high of $338. Looking at the price targets, the low is -0.65% off current price level while to achieve the yearly target high, price needs to move -9.74%. Nonetheless, investors will most likely welcome a -5.2% jump to $324 which is the analysts’ median price.
If we refocus on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), historical trading data shows that trading volumes averaged 1.04 million over the past 3 months. The company’s latest data on shares outstanding shows there are 130.31 million shares.
The 4.38% of Alnylam Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 96.24% of the company’s shares. Current price change has pushed the stock 30.89% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALNY stock continues to rise going into the next quarter.
